Celsion’s DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study … – Seeking Alpha
|
Celsion’s DNA immunotherapy candidate GEN-1 shows continued positive effect in early-stage ovarian cancer study …
Seeking Alpha Thinly traded nano cap Celsion (CLSN +129.8%) is up on a whopping 36x surge in volume in response to its announcement of final results from a Phase 1b dose-escalating study of DNA immunotherapy GEN-1 in patients with advanced Stage III/IV ovarian … Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special …Markets Insider Celsion Corporation (NASDAQ:CLSN) Stock Traded Higher Than Its 50 Day Moving AverageFirst News 24 |
|
CRISPR/Cas9 Disrupts Glaucoma Gene, Takes Pressure off Eyes in Disease Models
Genetic Engineering & Biotechnology News (blog) Scientists at the University of Iowa could be forgiven if they were to revise an old nursery rhyme to read, “two blind mice.” The scientists, led by Val Sheffield, M.D., Ph.D., used the CRISPR/Cas9 gene-editing system to disrupt a gene known to cause … |
Genetic Engineering & Biotechnology News |
Immunotherapy for Treating Malaria?
Genetic Engineering & Biotechnology News When we hear about immunotherapy these days, it’s most often associated with treatments or molecular pathways associated with cancer. But what if these immunological molecules could be exploited to treat one of the deadliest infectious diseases on the … |
|
Breakthrough cancer treatment brings hope and challenges
Science Daily The authors point out that as CAR T cell cancer treatments continue to be tested in clinical trials before obtaining FDA approval, “the FDA and Institutional Review Boards (IRBs) with oversight over human subjects research must carefully scrutinize … |
|
Twist Bioscience to Provide One Billion Base Pairs of Synthetic DNA to Ginkgo Bioworks to Support Expansion into …
Business Wire (press release) “An increasingly diverse scope of companies are looking to tap the power of biology to rethink traditional manufacturing, and demand for synthetic biology is at an all time high,” said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. “Our continued … |
Phys.Org |
Gold nanoparticle used to replace virus in new CRISPR approach
Phys.Org CRISPR-Cas9 has been in the news a lot lately because it allows researchers to directly edit genes—either disabling unwanted parts or replacing them altogether. But despite many success stories, the technique still suffers from a major deficit that … |
Phys.Org |
Gold nanoparticle used to replace virus in new CRISPR approach
Phys.Org CRISPR-Cas9 has been in the news a lot lately because it allows researchers to directly edit genes—either disabling unwanted parts or replacing them altogether. But despite many success stories, the technique still suffers from a major deficit that … |